Diabetes Complications Research Centre, Conway Institute and School of Medicine, University College Dublin, Dublin, Ireland.
Mater Misericordiae University Hospital, Eccles Street, Dublin 7, Ireland.
Atherosclerosis. 2024 Nov;398:118615. doi: 10.1016/j.atherosclerosis.2024.118615. Epub 2024 Sep 25.
Chronic kidney disease (CKD) is a significant health burden, with rising incidence and prevalence, attributed in part to increasing obesity and diabetes rates. Lipid accumulation in the kidney parenchyma and chronic, low-grade inflammation are believed to significantly contribute to the development and progression of CKD. The effect of dysregulated kidney lipid metabolism in CKD progression, including altered cholesterol and fatty acid metabolism contribute to glomerular and tubular cell injury through the activation of oxidative stress and inflammatory signalling cascades. In contrast, classes of endogenous specialized pro-resolving lipid mediators (SPMs) have been described that act to limit the inflammatory response and promote the resolution of inflammation. This review highlights our current understanding of how lipids can cause damage within the kidney, and classes of protective lipid metabolites that offer therapeutic benefits.
慢性肾脏病（CKD）是一个重大的健康负担，其发病率和患病率不断上升，部分原因是肥胖症和糖尿病发病率的上升。据信，肾脏实质中的脂质积累和慢性低度炎症对 CKD 的发展和进展有重大贡献。肾脏脂质代谢失调在 CKD 进展中的作用，包括胆固醇和脂肪酸代谢的改变，通过激活氧化应激和炎症信号级联反应，导致肾小球和肾小管细胞损伤。相比之下，已经描述了一类内源性专门的促解决脂质介质（SPM），它们通过限制炎症反应和促进炎症消退来发挥作用。这篇综述强调了我们目前对脂质如何在肾脏内造成损害的理解，以及提供治疗益处的保护性脂质代谢物类别。
